Mayne Pharma Group Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Mayne Pharma Group is gedaald met een gemiddeld jaarlijks percentage van -0.9%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks groeide met 35.4%. De inkomsten zijn daalde met een gemiddeld percentage van 16.6% per jaar.

Belangrijke informatie

-0.9%

Groei van de winst

0.9%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	31.2%
Inkomstengroei	-16.6%
Rendement op eigen vermogen	-37.1%
Nettomarge	-43.4%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Sep 01

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 06

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 01

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Nov 16

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Nov 10

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

May 17

Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

Mar 22

How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

Mar 01

What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Feb 08

Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Jan 18

Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Dec 27

Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?

Dec 09

A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation

Nov 24

Opbrengsten en kosten

Hoe Mayne Pharma Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

ASX:MYX Opbrengsten, kosten en inkomsten (AUD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	388	-169	243	20
31 Mar 24	354	-221	257	19
31 Dec 23	319	-274	272	18
30 Sep 23	251	-296	261	17
30 Jun 23	184	-317	251	16
31 Dec 22	59	-257	193	13
30 Sep 22	108	-233	187	12
30 Jun 22	157	-209	182	12
31 Mar 22	250	-151	184	15
31 Dec 21	342	-93	186	19
30 Sep 21	372	-151	179	20
30 Jun 21	401	-208	173	22
31 Mar 21	420	-232	180	22
31 Dec 20	439	-256	187	22
30 Sep 20	448	-174	194	24
30 Jun 20	457	-93	200	25
31 Mar 20	467	-196	210	26
31 Dec 19	478	-300	220	27
30 Sep 19	502	-290	231	28
30 Jun 19	525	-279	241	29
31 Mar 19	543	-118	230	27
31 Dec 18	561	43	219	25
30 Sep 18	546	-46	208	20
30 Jun 18	530	-134	197	15
31 Mar 18	526	-146	196	12
31 Dec 17	521	-158	194	8
30 Sep 17	547	-35	192	8
30 Jun 17	573	89	190	8
31 Mar 17	504	90	173	8
31 Dec 16	435	91	156	8
30 Sep 16	351	64	136	7
30 Jun 16	267	37	115	7
31 Mar 16	238	30	105	7
31 Dec 15	209	23	94	7
30 Sep 15	175	15	77	6
30 Jun 15	141	8	60	4
31 Mar 15	137	12	50	3
31 Dec 14	133	17	40	3
30 Sep 14	138	19	37	4
30 Jun 14	143	21	35	5
31 Mar 14	135	15	33	5
31 Dec 13	126	8	31	6

Kwaliteitswinsten: MYX is momenteel verliesgevend.

Groeiende winstmarge: MYX is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: MYX is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 0.9% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van MYX over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: MYX is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( 46.5% ).

Rendement op eigen vermogen

Hoge ROE: MYX heeft een negatief Return on Equity ( -37.13% ), omdat het momenteel verliesgevend is.

Mayne Pharma Group Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Recent updates

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Price target decreased by 12% to AU$6.09

New major risk - Financial position

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

New minor risk - Profitability

Consensus revenue estimates increase by 14%, EPS downgraded

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Consensus estimates of losses per share improve by 13%

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Independent Non-Executive Director recently bought AU$69k worth of stock

Consensus estimates of losses per share improve by 13%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

Independent Non-Executive Chairman recently bought AU$74k worth of stock

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Consensus revenue estimates fall by 19%

Price target decreased by 24% to AU$3.86

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Inaugural dividend of AU$0.065 per share

Consensus revenue estimates fall by 11%

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Consensus forecasts updated

Price target decreased to AU$0.37

Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Price target decreased to AU$0.40

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

Price target increased to AU$0.43

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Price target decreased to AU$0.36

Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 97%

Mayne Pharma Expands U.S Dermatology Portfolio

Price target increased to AU$0.48

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

High number of new directors

Independent Non Executive Director Bruce Mathieson has left the company

Independent Chairman Roger Corbett has left the company

Independent Chairman Roger Corbett has left the company

U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque Psoriasis

Independent Non-Executive Director recently bought AU$137k worth of stock

Price target decreased to AU$0.42

Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020)

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published